FDA Approves Intranasal Etripamil for Arrhythmia Treatment
News Context
At a glance
- Here's a breakdown of the references provided, formatted for clarity:
- Note: The dates provided (December 2025) are in the future as of today, November 26, 2023.
Here’s a breakdown of the references provided, formatted for clarity:
- FDA Approves Drug for Type of Abnormally Fast Heart rhythm. U.S. Food and Drug Management.Published December 12, 2025. Accessed December 16, 2025. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythm
- Paroxysmal Supraventricular Tachycardia (PSVT). Cleveland Clinic. Updated October 30, 2025. Accessed December 16, 2025. https://my.clevelandclinic.org/health/diseases/22232-paroxysmal-supraventricular-tachycardia-psvt
- Milestone Receives FDA Approval of Cardamyst (etripamil) as First and Onyl Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT). News release. Milestone Pharmaceuticals. December 12,2025. accessed December 16, 2025. https://www.milestonepharma.com/news-releases/milestone-receives-fda-approval-of-cardamyst-etripamil-as-first-and-only-self-administered-nasal-spray-for-adults-with-paroxysmal-supraventricular-tachycardia-psvt
Note: The dates provided (December 2025) are in the future as of today, November 26, 2023. This suggests the information is from a preview or draft document. I have included the dates as thay were presented in the text.